Comparative assessment of outcomes and adverse effects using two different intramuscular testosterone therapy regimens: 100 mg IM weekly or 200 mg IM biweekly

This study aimed to compare the change in levels of several laboratory values and the development of adverse events using two commonly used intramuscular testosterone therapy regimens. Men were included if they were 18 years or older and received one of the following testosterone therapy regimens: 1...

Full description

Saved in:
Bibliographic Details
Published in:International journal of impotence research 2022-09, Vol.34 (6), p.558-563
Main Authors: El-Khatib, Farouk M., Huynh, Linda M., Kopelevich, Alexei, Osman, Mohamad M., Choi, Edward, Nguyen, Jeanie T., Dianatnejad, Sharmin, Wu, Qiaqia, Olivas, Madeline G., Spitz, Aaron, Lowry, Jacob, Losso, Boriss Y., Khera, Mohit, Angulo-Llanos, Laura, Patel, Premal, Ramasamy, Ranjith, Yafi, Faysal A.
Format: Article
Language:English
Subjects:
692/699/2743/1526
692/700/565/2194
Antigens
Endocrine therapy
Medicine
Medicine & Public Health
Mens health
Prostate
Reproductive health
Reproductive Medicine
rology
Testosterone
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to compare the change in levels of several laboratory values and the development of adverse events using two commonly used intramuscular testosterone therapy regimens. Men were included if they were 18 years or older and received one of the following testosterone therapy regimens: 100 mg intramuscular once weekly or 200 mg intramuscular once every other week. Primary outcomes were relative changes in total testosterone, free testosterone, estradiol, prostate-specific antigen, and hematocrit at 6 months after initiation of testosterone therapy. Secondary outcomes were any significant rises in estradiol, hematocrit, prostate-specific antigen, and any other treatment-related adverse events requiring cessation of testosterone therapy. A total of 263 men were enrolled. In a subanalysis of men who had a baseline hematocrit below 54% before intramuscular testosterone therapy initiation, we found the following: men who received 100 mg weekly injections were significantly less likely to have hematocrit levels rising above 54% (1/102 (1%) vs. 4/51 (8%); p  = 0.023). No significant differences were recorded in the increase in total testosterone, free testosterone, prostate-specific antigen, and estradiol levels between both groups. A higher average serum testosterone over the dosing interval seen with the 200 mg regimen appears to be associated with a higher risk of erythrocytosis.
ISSN:0955-9930
1476-5489
DOI:10.1038/s41443-021-00449-0